Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.51 |
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.37 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908276 | 0.82 | POLB (0.52) | CD274PDCD1LG2POLBTDP1PDE10A | |
| SCHEMBL10369937 | 0.81 | POLB (0.45) | CD274PDCD1LG2POLBTDP1PDCD1 | |
| SCHEMBL2715698 | 0.80 | CD274 (0.43) | CD274PDCD1LG2POLBTDP1PDCD1 | |
| SCHEMBL10369005 | 0.80 | CD274 (0.43) | CD274PDCD1LG2POLBTDP1PDCD1 | |
| SCHEMBL2715306 | 0.80 | CD274 (0.43) | CD274PDCD1LG2POLBPDCD1LOXL2 | |
| SCHEMBL1848182 | 0.80 | POLB (0.46) | CD274PDCD1LG2POLBTDP1PDE10A | |
| SCHEMBL18291529 | 0.80 | POLB (0.46) | CD274PDCD1LG2POLBTDP1PDE10A | |
| SCHEMBL1904976 | 0.80 | NNMT (0.49) | CD274PDCD1LG2POLBTDP1LOXL2 | |
| SCHEMBL6408365 | 0.80 | POLB (0.50) | CD274PDCD1LG2POLBTDP1PDCD1 | |
| SCHEMBL5010358 | 0.80 | CD274 (0.51) | CD274PDCD1LG2PDCD1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-29 | — | — | US | disclosed |
| CN-102695417-A | Compounds and methods for kinase modulation and indications therefor | PLEXXIKON INC | 2012-09-26 | — | — | CN | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | CD274 741/4885PDCD1LG2 864/4885POLB 2684/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | CD274 4855/4885PDCD1LG2 4806/4885POLB 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.